Mental Health

George MacKinnon, PhD, MS, RPh, FASHP, FNAP, discussed how a multi-pronged approach to burnout is necessary in the pharmacy environment.

George MacKinnon, founding dean of the Medical College of Wisconsin School of Pharmacy and a professor there, discusses burnout in the pharmacy and how it can ultimately impact patients.

Mindfulness-based cognitive therapy helps change feelings and thoughts about experiences, minimizing depressive episodes, analysis indicates.

Analysis to be presented at the American College of Cardiology’s 71st Annual Scientific Session is based on the health records of 495,386 patients.

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

Thirty minutes of day of movement, such as walking, can help break the cycle of inflammation that causes symptoms even 6 months later.

Pharmacy Times spoke with Meagen Rosenthal, PhD, about her session at the APhA 2022 Annual Meeting and Exposition, titled "Heal Thyself: Burnout Recovery for Front-Line Heroes."

Adequate training will help them recognize signs of misuse and assist with preventive measures.

Prevalence is also linked to mental health conditions and substance use disorders, according to analysis.

The commission “Time for United Action on Depression,” authored by 25 experts from 11 countries, seeks to unify global efforts among governments, health care providers, researchers, people living with depression, and their families to improve care and prevention, fill knowledge gaps, and increase awareness.

David Drapkin, director of operations and strategic growth at Psychedelics Today, discussed the new Diversity, Equity, and Inclusion Training Fund for clinicians and practitioners in psychedelic medicine.

There are a few options that can help with the current mental health epidemic, although more studies are recommended to perfect these treatments.

Although biologic changes may occur in the body that affect the brain, nonbiologic changes, such as social isolation, can also be a part of it but the reasons are not completely clear, according to the study.

During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses how hypoactive sexual desire disorder in women was defined and treated historically.

In a phase 3 study, there were clinically and statistically significant changes observed from baseline to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients treated with cariprazine at 1.5 mg/day versus the placebo.

At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.

Vortioxetine (Trintellix) treats major depressive disorder in adults.

Process helps prevent errors for individuals with chronic disorders who often have a higher risk of drug-drug interactions.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses whether hypoactive sexual desire disorder is associated with psychological and/or emotional components.

All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, addresses how pharmacists can respond to questions patients may ask them about ketamine and other psychedelic treatments.

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, explains how ketamine infusions work when administered in patients’ homes and what safety precautions would be taken by providers in this setting.

Data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded treatment offering that would include psychedelic medicines.

Stacy Miller, PharmD, BCPP, the senior content management consultant at Wolters Kluwer Health, discusses clinician search data focused on mental health treatment trends and needs.

The research team found that levels of depression are at least 3 times higher than before the COVID-19 pandemic.

Bupropion (Aplenzin) is an antidepressant that treats major depressive disorder and seasonal affective disorder.

The men were assessed for neuroticism—or the tendency to interpret situations as stressful, threatening, or overwhelming—and worry levels through 2 mail-in surveys.

Symptoms of depression were reduced as quickly as 1 to 4 hours after a single treatment and lasted up to 2 weeks.